ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ: ACAD · IEX Real-Time Price · USD
16.61
+0.32 (2.00%)
Sep 27, 2022 3:45 PM EDT - Market open
2.00%
Market Cap 2.69B
Revenue (ttm) 512.40M
Net Income (ttm) -204.62M
Shares Out 161.84M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 826,894
Open 16.45
Previous Close 16.28
Day's Range 16.45 - 17.14
52-Week Range 12.24 - 28.06
Beta 0.67
Analysts Buy
Price Target 19.25 (+15.9%)
Earnings Date Nov 7, 2022

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 d... [Read more...]

Industry Biotechnology
IPO Date May 27, 2004
CEO Stephen Davis
Employees 540
Stock Exchange NASDAQ
Ticker Symbol ACAD
Full Company Profile

Financial Performance

In 2021, ACAD's revenue was $484.15 million, an increase of 9.60% compared to the previous year's $441.76 million. Losses were -$167.87 million, -40.38% less than in 2020.

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 19.25, which is an increase of 15.93% from the latest price.

Price Target
$19.25
(15.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review

The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.

2 weeks ago - Zacks Investment Research

Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepte...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinet...

2 weeks ago - Business Wire

Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference Fi...

3 weeks ago - Business Wire

Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade

The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

4 weeks ago - Zacks Investment Research

Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?

Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates

Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.

1 month ago - Zacks Investment Research

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022. “In the second quarter of 2022, NUPLAZID net sal...

1 month ago - Business Wire

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pima...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) reg...

1 month ago - Business Wire

Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. fi...

2 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals ...

NEW YORK , July 21, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ("Acadia" or the "Company")(NASDAQ: ACAD) and certain of i...

2 months ago - PRNewsWire

Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate

Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.

2 months ago - Zacks Investment Research

Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trof...

2 months ago - Business Wire

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive ...

ATLANTA--(BUSINESS WIRE)---- $ACAD #Alzamend--Alzamend Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depression, and Post-Traumatic Stress Disorder

2 months ago - Business Wire

Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why

The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.

2 months ago - Zacks Investment Research

Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?

Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.

3 months ago - InvestorPlace

Why Acadia Pharmaceuticals Stock Is Crashing Today

An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.

3 months ago - The Motley Fool

Why Acadia Pharma Shares Are Plunging Today

A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis. The d...

3 months ago - Benzinga

Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote

Shares of Acadia Pharmaceuticals Inc. ACAD, +3.94% were still down 30.5% in premarket trading on Tuesday, days after a Food and Drug Administration advisory committee voted against approval of the compa...

3 months ago - Market Watch

FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid

An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.

3 months ago - Zacks Investment Research

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the outcome of the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) meet...

3 months ago - Business Wire

Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's di...

Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a tre...

3 months ago - Market Watch

Acadia Pharmaceuticals Stock Trading Halted Today

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company's common stock. The U.S. Food and Drug Administration's Psychopharmac...

3 months ago - Business Wire